Amphastar Pharmaceuticals 

$19.63
284
-$0.46-2.29% Today

Statistics

Day High
20.29
Day Low
19.59
52W High
31.26
52W Low
16.65
Volume
252,819
Avg. Volume
590,298
Mkt Cap
890.61M
P/E Ratio
12.1
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
0.42
0.61
0.8
0.99
Expected EPS
0.638429
Actual EPS
N/A

Financials

13.63%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.44BRevenue
196.19MNet Income

Analyst Ratings

20.50Average Price Target
The highest estimate is 22.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMPH. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Show more...
CEO
Dr. Ziping Luo Ph.D.
Employees
2028
Country
United States
ISIN
US03209R1032

Listings

0 Comments

Share your thoughts

FAQ

What is Amphastar Pharmaceuticals stock price today?
The current price of AMPH is $19.63 USD — it has decreased by -2.29% in the past 24 hours. Watch Amphastar Pharmaceuticals stock price performance more closely on the chart.
What is Amphastar Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amphastar Pharmaceuticals stocks are traded under the ticker AMPH.
Is Amphastar Pharmaceuticals stock price growing?
AMPH stock has risen by +1.55% compared to the previous week, the month change is a +16.72% rise, over the last year Amphastar Pharmaceuticals has showed a -23.74% decrease.
What is Amphastar Pharmaceuticals market cap?
Today Amphastar Pharmaceuticals has the market capitalization of 890.61M
When is the next Amphastar Pharmaceuticals earnings date?
Amphastar Pharmaceuticals is going to release the next earnings report on August 10, 2026.
What were Amphastar Pharmaceuticals earnings last quarter?
AMPH earnings for the last quarter are 0.42 USD per share, whereas the estimation was 0.71 USD resulting in a -40.44% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amphastar Pharmaceuticals revenue for the last year?
Amphastar Pharmaceuticals revenue for the last year amounts to 1.44B USD.
What is Amphastar Pharmaceuticals net income for the last year?
AMPH net income for the last year is 196.19M USD.
How many employees does Amphastar Pharmaceuticals have?
As of June 15, 2026, the company has 2,028 employees.
In which sector is Amphastar Pharmaceuticals located?
Amphastar Pharmaceuticals operates in the Health & Wellness sector.
When did Amphastar Pharmaceuticals complete a stock split?
Amphastar Pharmaceuticals has not had any recent stock splits.
Where is Amphastar Pharmaceuticals headquartered?
Amphastar Pharmaceuticals is headquartered in Rancho Cucamonga, United States.